All Publications

Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

Flaxman A. et al, (2024), PLoS pathogens, 20

Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine.

Bissett C. et al, (2024), NPJ vaccines, 9

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.

Drury RE. et al, (2024), Nat Commun, 15

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.

Ni T. et al, (2023), iScience, 26

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.

Port JR. et al, (2023), Nature communications, 14

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial

Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.

Kaplonek P. et al, (2023), Nature immunology

COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.

Hotez PJ. et al, (2023), BMJ global health, 8

Factors, enablers and challenges for COVID-19 vaccine development.

Excler J-L. et al, (2023), BMJ global health, 8

Vaccine access, equity and justice: COVID-19 vaccines and vaccination.

Privor-Dumm L. et al, (2023), BMJ global health, 8

ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface

Zhang P. et al, (2023)

Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).

Koen AL. et al, (2023), Vaccine, 41, 3486 - 3492

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Saunders JE. et al, (2023), eBioMedicine, 90, 104523 - 104523

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.

Madhi SA. et al, (2023), The Lancet. Infectious diseases, 23, 295 - 306

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209

T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.

McMahon WC. et al, (2023), AIDS (London, England), 37, 105 - 112

Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters.

Port JR. et al, (2022), bioRxiv

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Flaxman A. et al, (2021)

Cookies on this website

All Publications